Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 18

Results For "biological"

231 News Found

Abbott recalls powder formula manufactured at Sturgis, Mich., plant
News | February 19, 2022

Abbott recalls powder formula manufactured at Sturgis, Mich., plant

Recall does not include any metabolic deficiency nutrition formulas


CDSCO recommends EUA for Corbevax in age group 12-18 years
News | February 15, 2022

CDSCO recommends EUA for Corbevax in age group 12-18 years

The recommendation has been sent to the DCGI for approval


X-Chem and Excelra's GOSTAR team up to discover drugs for challenging targets
Digitisation | February 10, 2022

X-Chem and Excelra's GOSTAR team up to discover drugs for challenging targets

GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets


Indian govt. places order for five crore doses of Corbevax
News | February 05, 2022

Indian govt. places order for five crore doses of Corbevax

Corbevax is administered through an intramuscular route with two doses scheduled 28 days apart and is stored between 2 degrees celsius to 8 degrees celsius


Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Drug Approval | January 20, 2022

Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide

Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach


China approves MIOK Keratoprosthesis’ artificial cornea
Biotech | January 19, 2022

China approves MIOK Keratoprosthesis’ artificial cornea

The artificial cornea is 100% made of non-biological materials and require no co-implantation of donor corneas and it is an ideal option for treating patients with corneal blindness


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Immune Biosolutions lead immunotherapy product neutralises Covid-19
Biotech | January 11, 2022

Immune Biosolutions lead immunotherapy product neutralises Covid-19

In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract


Algorithmic Biologics receives seed funding from Axilor Lab
Startup | January 11, 2022

Algorithmic Biologics receives seed funding from Axilor Lab

The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry